An exploration group, a subsidiary of UNIST, has divulged an original strategy to create a specific anticancer forerunner substance that targets and kills malignant growth cells. This pivotal technique, already existing just in principle, has now been tentatively demonstrated, interestingly opening up additional opportunities in the improvement of imaginative medications through a broad examination of the impacts of anticancer antecedents on the human body. Driven by Teacher Jaeheung Cho of the Division of Science at UNIST, the exploration group has effectively exhibited that the combination of hydroxymato cobalt (III), a potential competitor substance for anticancer forerunners, includes the response of